10-Q: Assertio Holdings Reports Mixed Q2 Results Amidst Generic Competition and Restructuring

Assertio Holdings' second quarter results show a net loss, impacted by generic competition for INDOCIN, while ROLVEDON sales continue to grow.

Summary

• Assertio Holdings reported a net loss of $3.674 million for the three months ended June 30, 2024, and a net loss of $8.184 million for the six months ended June 30, 2024.
• Product sales decreased to $30.695 million for the quarter and $62.557 million for the six months, primarily due to a decline in INDOCIN sales.
• ROLVEDON sales reached $15.144 million for the quarter and $29.622 million for the six months, showing growth but offset by lower net pricing.
• The company faced increased competition from generic versions of INDOCIN, leading to lower volume and pricing.
• Operating expenses increased due to costs associated with ROLVEDON and higher legal expenses.
• The company recognized a $1.9 million insurance reimbursement for previous opioid-related legal expenses.
• Amortization of intangible assets increased to $6.7 million for the quarter due to a revision in the useful life of INDOCIN product rights.
• The company has a full valuation allowance against its net deferred tax asset as of June 30, 2024.
• The company is involved in various legal proceedings, including opioid-related litigation and shareholder lawsuits.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like ROLVEDON growth, but the overall sentiment is negative due to the net loss, declining INDOCIN sales, and ongoing legal challenges. The company is facing significant headwinds.

Positives

• ROLVEDON sales showed quarter-over-quarter growth, reaching $15.144 million for the quarter.
• The company recognized a $1.9 million insurance reimbursement for previous opioid-related legal expenses.
• The company is actively managing its business and streamlining operations.

Negatives

• The company reported a net loss of $3.674 million for the quarter and $8.184 million for the six months.
• INDOCIN sales significantly decreased due to generic competition, falling to $6.913 million for the quarter.
• Total product sales decreased compared to both the previous quarter and the same period last year.
• Operating expenses increased due to costs associated with ROLVEDON and higher legal expenses.
• The company has a full valuation allowance against its net deferred tax asset as of June 30, 2024.

Risks

• The company faces increasing competition from generic versions of its products, particularly INDOCIN.
• The company is involved in various legal proceedings, including opioid-related litigation and shareholder lawsuits, which could result in significant expenses.
• The company's future financial performance is subject to the success of ROLVEDON and other products.
• The company's ability to maintain its supply chain, which relies on single-source suppliers, is a risk.
• The company's common stock may not maintain compliance with The Nasdaq Capital Markets minimum closing bid requirement.

Future Outlook

The company expects INDOCIN net product sales to continue to be impacted unfavorably by increasing competition from generic entrants. The company also expects cost of sales, as a percentage of sales, to be higher due to changes in product volume and mix when compared to 2023.

Management Comments

• The company is focused on managing supply costs and enhancing the long-term prospects of ROLVEDON product sales.
• The company is regularly evaluating its operations to identify opportunities to streamline operations and optimize operating efficiencies.

Industry Context

The pharmaceutical industry is facing increasing generic competition, which is impacting the sales of branded drugs like INDOCIN. Companies are focusing on new product launches and strategic acquisitions to maintain growth.

Comparison to Industry Standards

• The decline in INDOCIN sales due to generic competition is a common trend in the pharmaceutical industry, impacting companies like Teva and Mylan who also face generic erosion of their branded products.
• The growth of ROLVEDON sales is a positive sign, but its success will be crucial for Assertio's future performance, similar to how companies like Amgen rely on key product launches.
• The legal expenses and restructuring costs are impacting profitability, which is a common challenge for companies undergoing mergers and acquisitions, similar to the integration challenges faced by companies like AbbVie after acquiring Allergan.
• The company's focus on streamlining operations and optimizing efficiencies is a standard practice in the industry to manage costs and improve profitability, similar to cost-cutting measures implemented by companies like Pfizer.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business.
• The company is involved in antitrust litigation related to its former drug Glumetza.
• The company is subject to opioid-related requests and subpoenas from various government agencies.
• The company is involved in multidistrict and other federal opioid litigation.
• The company is involved in state opioid litigation.
• The company has learned of a qui tam lawsuit filed against Depomed, Inc. (now known as Assertio Therapeutics).
• The company is involved in insurance litigation.
• The company is involved in stockholder actions, including Shapiro v. Assertio Holdings, Inc., et al., Edwards v. Assertio Holdings, Inc., et al., Jung v. Peisert, et al., Hollin v. Mason, et al., Jung v. Lebel, et al., Luo v. Spectrum Pharmaceuticals, Inc., et al., Christiansen v. Spectrum Pharmaceuticals, Inc. et al., Csaba v. Turgeon, et. al., Shumacher v. Turgeon, et. al., Johnson v. Turgeon, et. al., Raul v. Turgeon, et. al., and Albayrak v. Turgeon, et. al.

Stakeholder Impact

• Shareholders are impacted by the net loss and declining stock price.
• Employees are impacted by the reorganization plan and potential job losses.
• Customers may be impacted by changes in product availability and pricing.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors are impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company will continue to focus on the commercialization of ROLVEDON.
• The company will continue to manage its supply chain and costs.
• The company will continue to defend itself in ongoing legal proceedings.

Key Dates

Keywords

ROLVEDON, INDOCIN, generic competition, pharmaceuticals, net loss, product sales, restructuring, legal proceedings, amortization, opioid litigation